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Abstract
The capsule of Streptococcus pyogenes serves as an adhesin as well as an anti-phagocytic factor by binding to CD44 on
keratinocytes of the pharyngeal mucosa and the skin, the main entry sites of the pathogen. We discovered that S. pyogenes
HSC5 and MGAS315 strains are further thermoregulated for capsule production at a post-transcriptional level in addition to
the transcriptional regulation by the CovRS two-component regulatory system. When the transcription of the hasABC
capsular biosynthetic locus was de-repressed through mutation of the covRS system, the two strains, which have been used
for pathogenesis studies in the laboratory, exhibited markedly increased capsule production at sub-body temperature.
Employing transposon mutagenesis, we found that CvfA, a previously identified membrane-associated endoribonuclease, is
required for the thermoregulation of capsule synthesis. The mutation of the cvfA gene conferred increased capsule
production regardless of temperature. However, the amount of the capsule transcript was not changed by the mutation,
indicating that a post-transcriptional regulator mediates between CvfA and thermoregulated capsule production. When we
tested naturally occurring invasive mucoid strains, a high percentage (11/53, 21%) of the strains exhibited thermoregulated
capsule production. As expected, the mucoid phenotype of these strains at sub-body temperature was due to mutations
within the chromosomal covRS genes. Capsule thermoregulation that exhibits high capsule production at lower
temperatures that occur on the skin or mucosal surface potentially confers better capability of adhesion and invasion when
S. pyogenes penetrates the epithelial surface.
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Introduction
S. pyogenes, also known as Group A Streptococcus (GAS), is a
Gram-positive human pathogen that causes a variety of diseases
ranging from mild superficial infections such as impetigo and
pharyngitis to life-threatening invasive or toxigenic diseases
including myositis, necrotizing fasciitis, and streptococcal toxic
shock syndrome. Immune-mediated post-streptococcal sequelae
such as rheumatic fever and acute glomerulonephritis may develop
following acute GAS infections such as pharyngitis. Diseases
caused by S. pyogenes are a major public health concern both in
developed and developing countries. A recent survey estimated
that severe GAS diseases (post infectious sequelae and invasive
infections) cause over a half million deaths each year [1]. More
than 30 million cases of streptococcal pharyngitis and approxi-
mately 9,000–12,300 cases of invasive GAS disease occur each
year in the U.S (see http://www.cdc.gov/abcs/reports-findings/
surv-reports.html).
There is undoubtedly a complex interplay between the levels of
expression of various bacterial virulence factors and environmental
factors. Temperature shifts are important environmental signals
that pathogens frequently encounter when initiating infection,
since internal host temperatures are higher than environmental or
external host surface temperatures. Thermoregulation of virulence
factor levels potentially contributes to attachment to or invasion of
host tissues through enhanced expression of adhesins or anti-
phagocytic factors and reduced expression of proteins normally
targeted by the host immune responses [2,3].
The S. pyogenes capsule is an adhesin involved in initial
colonization at the lower temperatures typical of the mucosal
surfaces of the throat or on the skin [4,5,6], and also serves as an
antiphagocytic factor during invasive infections [7]. The capsule is
composed of hyaluronic acid, the same polysaccharide found in
human connective tissue, and binds to CD44 located on the
surface of keratinocytes on the pharyngeal mucosa and the skin
[5]. This activity of the S. pyogenes capsule promotes colonization
and initiation of a new cycle of infection. The capsule biosynthetic
operon is comprised of the hasA, hasB, and hasC genes, which
encode hyaluronic acid synthetase, UDP-glucose dehydrogenase,
and UDP-glucose pyrophosphorylase, respectively [8,9,10,11].
The third gene in the operon hasC, however, is not required for
capsule production due to the existence of another gene of UDP-
glucose pyrophosphorylase in the genome [12,13]. The transcrip-
tion of the hasABC operon is under the control of a single upstream
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promoter [11,14] that is regulated by the CovRS (also called
CsrRS) two-component regulatory system, in which CovR is the
response regulator and CovS is the sensor kinase [15]. The CovRS
two-component system influences the expression of a large regulon
that includes many virulence genes (reviewed in [16]). CovR
primarily acts as a transcriptional repressor of genes that encode
virulence factors, thus disruption of covR or covS affects the
virulence of S. pyogenes in animal models (reviewed in [16]). Here
we demonstrate that in a significant subset of invasive strains that
contain defects in the covRS genes, the production of the GAS
capsule adhesin and antiphagocytic factor is additionally con-
trolled at a post-transcriptional level by environmental tempera-
ture. We speculate that through overproducing the capsule
adhesin at sub-internal body temperatures these variants attach
more effectively to epithelial cells, and that upon epithelial
penetration, the thicker capsular layer potentially protects against
the initial phagocytic attack leading to the systemic spread of
invading GAS.
Previously we demonstrated that the GAS CvfA, a putative
membrane-associated endoribonuclease, influences the expression
of several virulence factors including M protein (cell wall-anchored
protein exerting activities of adhesion and immune evasion),
streptokinase (protease activating blood clot-cleaving enzyme
plasmin), the CAMP factor (co-hemolysin), and SpeB (major
secreted protease) in response to growth stages and nutritional
stress [17]. Here we demonstrate that CvfA is also essential for
thermoregulation of capsule synthesis.
Materials and Methods
Bacterial strains and media
Laboratory strains used in this study are listed in Table 1. S.
pyogenes HSC5 [18] and MGAS315 [13] were used for most
experiments and strain construction. HSC5 is a non-mucoid lab
strain that has been studied for several streptococcal virulence
factors and their regulations (selected references; [17,18,19,20,
21,22,23,24]). MGAS315 is a non-mucoid clinical strain isolated
from a patient with streptococcal toxic shock syndrome, and its
genome sequence is publically available [13]. Escherichia coli DH5a
[25] or TOP10 (Invitrogen) was cultured in Luria-Bertani broth
and was employed for plasmid construction. S. pyogenes was
routinely cultured in Todd-Hewitt medium (BBL) supplemented
with 0.2% yeast extract (Difco) at 37uC in sealed tubes without
agitation. For solid media, Bacto agar (Difco) was added to a final
concentration of 1.4% (w/v). Cultures on solid media were
incubated under anaerobic conditions (,0.03% O2 and 15%
CO2) employing a commercial gas generator (GasPak EZ
Anaerobe container system). When appropriate, antibiotics were
added to the media at the following concentrations unless
specified; spectinomycin 100 mg/ml for E. coli and S. pyogenes;
kanamycin 50 mg/ml for E. coli and 500 mg/ml for S. pyogenes;
erythromycin 500 mg/ml for E. coli and 1 mg/ml for S. pyogenes;
chloramphenicol 7 mg/ml for E. coli and 3 mg/ml for S. pyogenes.
Manipulation of DNA
Plasmid DNA was isolated by standard techniques and used to
transform E. coli by the method of Lederberg and Cohen [17].
Transformation of S. pyogenes was performed by electroporation as
described previously [26]. Restriction endonucleases, ligases, and
polymerases were used according to the recommendations of the
manufacturers. Chromosomal DNA was purified from S. pyogenes
using GenEluteTM Bacterial Genomic DNA Kit (Sigma). When
required, DNA fragments were purified using Mini EluteTM gel
extraction kit (Qiagen) following agarose gel electrophoresis.
Transposon mutagenesis
For transposon mutagenesis, TnVKm2, a TnSpc derivative
containing a kanamycin resistance determinant, was employed. In
TnVKm2, the spectinomycin gene (aad9) in TnSpc (for the genetic
structure of this transposon, refer to Figure 1 in [23]) was replaced
with VKm2, which is the kanamycin resistant determinant aphA-3
flanked by a strong Rho-independent transcriptional terminator at
both ends. The construction process of VKm2 was described
elsewhere [27]. Construction of a library of transposon insertions
was conducted as described elsewhere [23]. Transposon insertion
sites were identified by direct sequencing of chromosomal DNA
with a primer binding to a site within the transposon. Comparison
to the genomic database (http://www.ncbi.nlm.nih.gov/BLAST/)
was used to identify the site of a transposon insertion.
Strain construction
Insertional disruption of the covR gene. The covR (also
known as csrR, genomic locus SPyM3_0224) gene was disrupted by
single crossover homologous insertion as follows: An internal
region of covR was amplified by PCR, then inserted into the suicide
vector pSPC18 [28]. The resultant plasmid was used to transform
HSC5 or MGAS315. To ensure that strain phenotypes occurred
specifically due to gene disruption and not to a non-specific effect
of integration of pSPC18 into the chromosome, HSC5Spc
(Table 1) was included in selected analyses as a wild type control
strain for pSPC18 insertion [21].
In frame deletion of the covR gene. An in frame deletion in
the covR gene was constructed as follows. The PCR primers,
5IFDcovRoutHind (AAAAAAGCTTTTGGGCAGTTTTGA-
CAGAAG) and 3IFDcovRoutBam (AAAAGGATCCTTGTGA-
TATCGCGCTCACTC), were used to amplify a region of the
chromosome that includes the entire covR open reading frame
using the high fidelity DNA polymerase Pfu (Invitrogen). The
resulting fragment was inserted into the E. coli-streptococcal shuttle
vector pJRS233 [29] after digestion with HindIII and BamHI. The
resulting plasmid (pJRS233::covR) was then used as the template in
an inverse PCR reaction with primers 5IFDcovRinXma
(AAAACCCGGGTTTGGAAATATGATGAAGCCG) and
3IFDcovRinXma (AAAACCCGGGACCCTTCACGACCATT-
GAC). This PCR product was digested with XmaI, then subjected
to ligation and used to transform E. coli. The resulting plasmid,
pJRS233::covRIFD, contained a 145 codon deletion derivative of
covR with a unique XmaI site inserted at the deletion site (between
codons 38 and 184 in covR). This allele was used to replace the wild
type covR gene of HSC5.
Cis-complementation with the cvfA gene. Complemen-
tation of the transposon-inserted cvfA was performed with a
method described elsewhere (For the scheme of complementation,
refer to the Figure 1 in [17]). Briefly, the chromosomal region
containing the cvfA gene and its putative promoter was amplified
by PCR and inserted into the suicide vector pSPC18. The
transposon-generated CvfA null strains were then transformed
into strains producing CvfA by electroporating the cvfA-containing
pSPC18. In the transformation process, the wild type cvfA allele in
pSPC18 was inserted after the mutant allele, and this insertion was
confirmed by PCR and restoration of the expression of SpeB, the
major secreted protease, which is not produced from CvfA null
strains [17].
Trans-complementation with hasABC. To express the
hasABC transcript under a heterologous promoter, the entire
hasABC genes including its ribosome-binding site was PCR-
amplified and inserted downstream of the rofA promoter in the
E. coli – S. pyogenes shuttle vector, pABG5. The rofA promoter was
chosen because its transcription activity is not influenced by the
Capsule Thermoregulation by S. pyogenes
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Table 1. Bacterial strains and plasmids.
Strain/plasmid Relevant genotype/description
Reference/
source
Strains
E. coli
DH5a endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG W80dlacZDM15 D(lacZYA-argF)U169,
hsdR17(rK
2 mK
+)
[25]
TOP10 mcrA D(mrr-hsdRMS-mcrBC) Q80lacZDM15 DlacX74 nupG recA1 araD139 D(ara-leu)7697
galE15 galK16 rpsL(StrR) endA1
Invitrogen
S. pyogenes
HSC5 Wild type, M14 serotype [18]
HSC5Spc Wild type control strain for pSPC18 insertion. pSPC18 is inserted into the HSC5
chromosome without disrupting any gene or operon.
[21]
VCovR HSC5 strain with disrupted covR by a plasmid insertion. An internal part of covR (0.39 kb) was
amplified by PCR, inserted into the suicide vector, pSPC18, and transferred into HSC5.
[20]
VCovR(pCovRS) VCovR with the covRS genes expressed on pABG5. This study
CovRIFD HSC5 strain with in-frame deleted covR. This strain has a deletion from the leucine codon (L39) to
valine codon (V183) in the gene of CovR (228 amino acid long). Refer to Materials and Methods.
This study
CovRIFD:VSPy_2199 CovRIFD with disrupted SPy_2199 by the suicide vector pSPC18::’SPy_2199’ This study
HasA-HA HSC5 strain producing HA (hemagglutinin) epitope - tagged HasA. The tagging was performed
through homologous recombination using pCIV::hasA-HA.
This study
CovRIFD:HasA-HAkm CovRIFD strain producing HA (hemagglutinin) epitope -tagged HasA. The tagging was
performed through homologous recombination using pCIV::hasA-HA.
This study
CovRIFD:HasA-HAspc CovRIFD strain producing HA (hemagglutinin) epitope -tagged HasA. The tagging was
performed through homologous recombination using pSPC18:: ’hasA-HA.
This study
CovRIFD:TnCvfA1 & CovRIFD:TnCvfA2 CovRIFD strains with transposon-generated CvfA2 mutation This study
CovRIFD:TnCvfA1:HasA-HA CovRIFD:TnCvfA1 strain producing HA (hemagglutinin) epitope -tagged HasA. The tagging
was performed through homologous recombination using pSPC18:: ’hasA-HA.
This study
CovRIFD: TnCvfA1Comp CovRIFD:TnCvfA1 with pCvfA insertion into the chromosome. The disrupted cvfA in
CovRIFD:TnCvfA1 was restored by inserting an intact copy of cvfA
This study
VHasA HSC5 strain with disrupted hasA [20]
VHasA(pHasABC) VHasA with hasABC expressed on pABG5 This study
CovRIFD:VHasA CovRIFD with disrupted hasA This study
CovRIFD:VHasA(pHasABC) CovRIFD:VHasA with hasABC expressed on pABG5 This study
CovRIFD:TnCvfA1:VHasA CovRIFD:TnCvfA1 strain with disrupted hasA This study
CovRIFD:TnCvfA1:VHasA(pHasABC) CovRIFD:TnCvfA1:VHasA with hasABC expressed on pABG5 This study
MGAS315 Wild type, M3 phenotype [13]
MGAS315:VCovR MGAS315 strain with disrupted covR. The same method to create HSC5 VCovR was used. This study
Plasmids
pSPC18 pUC18-based streptococcal integration vector containing aad9 (spectinomycin resistance
gene from Enterococcus faecalis).
[28]
pCIV2 pUC18-based streptococcal integration vector containing aphA3 (kanamycin resistance gene). [77]
pABG5 pNZ12-based multi-copy E. coli – S. pyogenes shuttle vector. Streptococcal genes can be
expressed under the rofA promoter.
[37,78]
pCovRS pABG5 containing the covRS genes (2.26-kbp) expressed under the rofA promoter. The covRS genes
were amplified by PCR with the primers of 5covRSEcoRI (AAAGAATTCGAGGATAAGGGTTGGTATAA) and
3covRSHAPstI (AAACTGCAGCTAAGCGTAATCTGGAACATCGTAGCTGGTACTCTCTTTAGACTGGGCCAAAGG)
and inserted at the downstream of the rofA promoter on pABG5.
This study
pSPC18::’SPy_2199’ pSPC18 containing a 0.63-kbp internal fragment of spy_2199 amplified by PCR with the
primers of 5KOSPyM3_1850BamHI (AAAAGGATCCCGCCCAGTATCAGCCTAAAG) and 3KOSPyM3_
1850BamHI AAAAGGATCCCGTTTTAATGCGATGTTGACTG
this study
pCIV2::hasA-HA pCIV2 containing a 1.4 kbp DNA fragment amplified by PCR with the primers of
hasAcompEcoRI-f (CGGAATTCTTAAAAATATTTCTATGACTAGTTGAC) and hasAcompHAPstI-r
(AACTGCAGTTAAGCGTAATCTGGAACATCGTATGGGTATTTAAAAATAGTGACCTTTTTACGTG). The DNA
fragment contains HA sequence (AGCGTAATCTGGAACATCGTATGGGTA) fused to the 39 side of hasA.
this study
pSPC18::’hasA-HA pSPC18 containing a 1.0 kbp DNA fragment amplified by PCR with the primers of 5hasAPstI
(AACTGCAGGAGTTCAAACACAGATGCAATAC) and hasAcompHAPstI-r
(AACTGCAGTTAAGCGTAATCTGGAACATCGTATGGGTATTTAAAAATAGTGACCTTTTTACGTG). The DNA
fragment contains HA sequence (AGCGTAATCTGGAACATCGTATGGGTA) fused to the 39 side of hasA.
this study
Capsule Thermoregulation by S. pyogenes
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37367
CovRS two-component system [30] nor environment temperature
[31]. For this construction, we employed ligase-independent
cloning described elsewhere [32]. Briefly, the vector pABG5 was
amplified with 59 phosphorylated primers, pABG5EcoRIup-LIC
(59P-ATTGGATTGGAAGTACGAATTCAGTTCCTCACAA-
TAATGG) and pABG5BanIdn-LIC (59P- ATTGGAAGTGGA-
TAACGGCACCGGGCAAAAAGCTG), and the insert, hasABC,
was amplified with primers 5hasABC-LIC (TACTTCCAATC-
CAATGAAAAGAAAGAGGTGTAATTGTGCC) and 3hasABC-
LIC (TTATCCACTTCCAATGCTCTAGTAAAGTTGTA-
TAACACAAAAC). The high fidelity DNA polymerase Pfu
(Invitrogen) was used for the PCR reaction. After purified with
the Mini EluteTM PCR purification kit (Qiagen), each PCR-
amplified product was treated with T4 DNA polymerase and
dGTP (for vector) or dCTP (for insert) at 25uC for 30 min, then
75uC for 20 min. This T4 DNA polymerase treatment with one
nucleotide generates single-stranded 59 ends (ATTGGATTG-
GAAGTA and ATTGGAAGTGGATAA for the vector,
TACTTCCAATCCAAT and TTATCCACTTCCAAT for the
insert) due to its 39 to 59 exonuclease activity. The exonuclease
activity stops when T4 DNA polymerase meets the same
nucleotide in DNA as the nucleotide added to the reaction. After
mixing the vector and the insert for 20 min at room temperature,
10 ml of the mixture was used to transform E. coli.
The details of each plasmid construct, the sequences of the
primers used to amplify DNA segments and the transformed
strains are listed in Table 1. Relevant strain constructs were
confirmed by examining their phenotypes or PCR using appro-
priate primers.
Tagging HasA with the hemagglutinin (HA) epitope. To
examine the expression level of the capsule gene product with
Western blot, the first gene product of the capsule transcript,
HasA, was tagged with a 9 residue hemagglutinin (HA) epitope
(YPYDVPDYA) by single cross-over homologous insertion as
follows: To fuse the HA epitope sequence (AGCGTAATCTG-
GAACATCGTATGGGTA) to the 39 side of hasA, the hasA gene
was amplified through PCR in which the 39 primer contained the
sequence of the HA epitope. The amplified product, the hasA gene
tagged with the HA epitope sequence, was then inserted into a
suicide vector, pCIV2 (kanamycin resistant) or pSPC18 (spectino-
mycin resistant). The pCIV2-based construct was used to
transform HSC5 and CovRIFD to HasA-HA and CovRIFD:-
HasA-HA1 respectively, and the pSPC18-based plasmid was used
to transform CovRIFD and CovRIFD:TnCvfA1 (kanamycin-
resistant) to CovRIFD:HasA-HA2 and CovRIFD:TnCvfA1:-
HasA-HA.
Table 1. Cont.
Strain/plasmid Relevant genotype/description
Reference/
source
pCvfA pSPC18 containing an intact copy of cvfA (1.80 kbp) amplified by PCR with the primers of
CvfAcompSphI-f (ACATGCATGCGAAGCCTACATCATGGACGAC) and CvfAcompSphI-r
(TTTTGCATGCCTACTTGGCATAATCAACCG)
this study
pHasABC pABG5 containing the hasABC genes (3.76-kbp) expressed under the rofA promoter. The hasABC
genes were amplified by PCR with the primers of 5hasABC-LIC
(TACTTCCAATCCAATGAAAAGAAAGAGGTGTAATTGTGCC) and 3hasABC-LIC
(TTATCCACTTCCAATGCTCTAGTAAAGTTGTATAACACAAAAC) and inserted at the downstream of
the rofA promoter on pABG5.
This study
Restriction sites embedded into primer sequences are italicized.
doi:10.1371/journal.pone.0037367.t001
Figure 1. Capsule thermoregulation occurs at a post-transcrip-
tional level. (A) The ratio of the capsule transcript quantity of the CovR
null strain to that of the wild type. S. pyogenes cells were grown on THY
agar plates at 37uC overnight (,18 hrs) and the fully grown colonies
were incubated for another six to eight hrs at each temperature (25uC
or 37uC). After RNA was extracted from the colonies, the relative
amounts of the capsule transcript between strains were measured
through real time-RT (reverse transcriptase) PCR. Regardless of the
incubation temperatures, the capsule transcript quantity in the CovR2
strain was more than 100 times higher than that in the wild type,
confirming that the CovRS two-component system regulates the
expression of the capsule transcript at the transcriptional level. (B)
The ratio of the capsule transcript quantity at 25uC to that at 37uC.
Regardless of the incubation temperatures, the capsule transcript
quantity in both strains (the wild type and the CovR2 strain) was the
same, indicating that thermoregulation of capsule production occurs at
a post-transcriptional level. The following strains were used: wild type
(WT), HSC5; CovR2 strain (CovR2), CovRIFD.
doi:10.1371/journal.pone.0037367.g001
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37367
Quantitation of S. pyogenes capsule
To determine the amount of hyaluronic acid capsule produced
by S. pyogenes on agar plates, a spectrophotometric assay using the
cationic carbocyanine dye, 1-ethyl-2-[3-(1-ethylnaphtho-[1,2-
d]thiazolin-2-ylidene)-2-methylpropenyl]naptho-[1,2-d]thiazolium
bromide (Sigma Chemical Co., St. Louis, MO) was developed
[33]. Overnight liquid culture of S. pyogenes grown in THY
medium at 37uC was serially diluted with PBS buffer to allow
plating less than 30 colonies on THY agar plates, which were
incubated at 37uC overnight (18,24 hrs) in anaerobic jars. These
plates were further incubated at different temperatures (25uC,
30uC, or 37uC) for six to eight hrs to examine the influence of
incubation temperature on capsule production. Afterwards, single
colonies were taken from the agar plate with a microspatula
(Fisher, Ca. # 21-401-10) and suspended by vortexing in 10 ml of
sterile deionized water. After suspension, a portion of the solution
was taken to determine the number of colony-forming units
(CFUs) by plating after serial dilution. If necessary, the chains of S.
pyogenes cells were broken by vigorous agitation or vortexing before
plating. After precipitating the cells through centrifugation at
6,0006 g for 10 min, the capsule-containing supernatant was
mixed with an equal volume of capsule-staining reagent (20 mg of
the cationic carbocyanine dye and 60 ml of glacial acetic acid in
50 ml of 50% formamide). The absorbance of the mixture was
then measured at an OD of 640 and the amount of capsule was
calculated using a standard curve generated with known concen-
trations of hyaluronic acid. The amount of capsule (femtogram per
CFU) was calculated from the quantity of capsule. Capsule
quantitation was performed in triplicate for each sample and at
least twice per each strain.
RNA isolation and real time RT-PCR
Reverse-transcriptase real-time RT-PCR with RNA isolated
from S. pyogenes was carried out as previously described [19].
Quantitation of capsule transcript employed two primer pairs to
separately target hasA and hasB. The sequences of primers used to
examine the expression of hasA were ATGCTGCAACAGGA-
CATTTG and TTAATGATTGAGCAGCACGC, which ampli-
fy a middle region (114 bps from 470th to 583rd) of hasA
(1188 bps), and those used to examine the hasB expression were
TCCCCAAACGCTAATTGAAG and TTTACTGGG-
GACTCCTGCTC, which amplify a 39 region (105 bps from
825th to 929th) of hasB (1209 bps). As expected, the primer sets
revealed the transcript amount of hasA was the same as that of
hasB. Since these primers cover most parts of the transcript of hasA
and hasB that are essential genes for capsule production, it is highly
likely that hasA and hasB in the capsule transcript in the tested
strains are intact. The gyrase subunit A gene (gyrA), whose
expression was determined with the primers, AACAACTCAAA-
CAGGTCGGG and CTCCTTCACGGCTAGATTCG, was
chosen as an internal control to normalize the expression of the
capsule transcript between samples. The gyrA gene was previously
used in a study of S. pyogenes gene expression upon temperature
shift [31], and we confirmed through quantitative RT-PCR that
the expression level of the gyrA gene did not change at different
temperatures ranging from 25uC–37uC. Data reported represent
the mean derived from a minimum of 2 independent experiments
each performed on a different day. Each data point was
determined through at least duplicate testing.
Examination of HasA expression level using Western
blotting
The strains with HasA tagged with a 9 residue hemagglutinin
(HA) peptide were grown on THY agar plates as described in the
procedure for capsule quantitation. Colonies (,100) were
suspended in 1 ml PBS buffer prewarmed at 25uC or 37uC, lysed
with a bead beater (FastPrep Instrument, MP biomedicals) at the
speed of 6.0 for 30 sec twice, and boiled immediately for 10 min.
This procedure was performed either in the lab (,25uC) or in a
37uC culture room. The samples were then centrifuged for 5 min
at the speed of 15,0006 g to discard cell debris. The supernatant
was transferred into a new tube, and the total protein amount was
measured using the Bradford assay method. 10 mg of total protein
was loaded onto an 8% SDS-PAGE gel and electrophoresed at
100 V for ,2 hrs. The separated proteins on the gel were then
transferred to a nitrocellulose membrane by electroblotting. After
the transfer, colorimetric detection for the HA epitope on the
membrane was performed by applying a rabbit anti-HA antibody
(primary antibody, Invitrogen, 1:1000 dilution), a goat anti-rabbit
IgG antibody conjugated with HRP (horse radish peroxidase)
(secondary antibody, Cell signaling, 1:5000 dilution), and in turn
the Bio-Rad Opti-4CN reagent. As an internal control for Western
blotting, the expression level of SPy_2184, a membrane anchored
protein (,74 kDa) with a putative function of cyclic-di-AMP
specific phosphodiesterase was determined. The expression of
SPy_2184 is not controlled by the CovRS two-component system
[30] or temperature (this study).
Hyaluronidase activity assay
Hyaluronidase activity was determined by using an agar plate
assay described elsewhere [34]. We used the Streptococcus pneumoniae
1121 Smr strain and its Dhyl mutant as a hyaluronidase positive
and a negative control strain, respectively [35].
Results
Temperature-dependent capsule production by CovR
null strains
To investigate the thermoregulation of capsule production, S.
pyogenes strains were plated (10–50 colonies per plate) on THY agar
plates and incubated at 37uC anaerobically overnight (18–24 hrs).
The fully-grown colonies were then incubated further for 6 to
8 hrs at each temperature tested (25uC, 30uC, or 37uC). The
amount of hyaluronic acid capsule produced by each colony was
then measured with a spectrophotometric assay.
CovR null strains of wild type S. pyogenes HSC5 and MGAS315
exhibited a high quantity of capsule only at temperatures below
37uC. Three CovR null strains were constructed for this assay:
VCovR [20], a HSC5 CovR2CovS2 strain with insertionally
disrupted covR; CovRIFD, HSC5 CovR2CovS+ strain with an in-
frame deletion of covR (leucine-39 through valine-183); and
MGAS315VCovR, an MGAS315 CovR2CovS2 strain with
insertionally disrupted covR. Since covS is cotranscribed with covR,
VCovR strains, whose covR was disrupted by a plasmid insertion
produce neither CovR nor CovS [36]. All three CovR null strains
produced 10 to 20 times more capsule at 25uC than at 37uC
(Table 2). As expected, the wild type non-mucoid strains, HSC5
and MGAS315 expressed capsule at basal levels regardless of
incubation temperature. When the capsule production of the
CovR null strains incubated at 25uC, 30uC, or 37uC was
compared, more capsule was produced at lower incubation
temperatures (Table 2), indicating that capsule thermoregulation
is gradual and is not regulated by an on/off mechanism.
Capsule Thermoregulation by S. pyogenes
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37367
The capsule amount produced by fully-grown covR null strain
colonies under ambient air (20% O2 and 0.03% CO2) was not
different from that under the anaerobic condition (,0.03% O2
and 15% CO2) (data not shown). Thus, the presence of oxygen or
increased carbon dioxide concentration did not affect thermoreg-
ulation of capsule synthesis.
The open reading frame immediately upstream of the capsule
operon, SPy_2199, a divergently transcribed gene encoding a
putative protease, was disrupted in CovRIFD, and the resultant
strain, CovRIFD VSPy_2199 showed the same phenotype of
capsule thermoregulation as that of CovRIFD (Table 2), indicating
no involvement of the upstream gene in capsule thermoregulation.
Complementation of the covR null strain VCovR
Disruption of the covR gene also prevents the expression of the
downstream gene covS since they are expressed under the same
promoter. Thus, for trans-complementation of VCovR, both covRS
genes (2.26 kb) were PCR-amplified and inserted downstream of
the rofA promoter in the multi-copy plasmid pABG5 [37]. The
promoter of rofA, the gene of a transcriptional activator (RofA,
SPy_0124) regulating the expression of prtF1 (fibronectin-binding
protein 1), confers high expression on pABG5 [37]. When
introduced into VCovR, the resulting plasmid pCovRS restored
the wild-type phenotype (Table 2), confirming that the CovRS
two-component system overrides capsule thermoregulation.
Capsule thermoregulation occurs at a post-
transcriptional level
To investigate the mechanism of capsule thermoregulation, we
determined the relative amounts of the hasABC capsule transcript
at different incubation temperatures using real-time RT-PCR.
Regardless of incubation temperature, the level of the capsule
transcript in CovRIFD was about 100 times more than that in the
wild type, HSC5 (Figure 1A). This result confirmed the previous
finding that the CovRS two-component system represses the
capsule gene expression at the transcriptional level [15,30,38].
Interestingly, the level of the capsule transcript in CovRIFD grown
at 25uC was almost the same as that in CovRIFD grown at 37uC
(Figure 1B), even though the capsule amount of CovRIFD
incubated at 25uC was about 17 times more than that incubated
at 37uC (Table 2). This result suggests that the increased capsule
amount of CovRIFD at the lower temperature resulted from a
post-transcriptional event.
We also analyzed the amount of a HasA-HA fusion product
(HasA tagged with the hemagglutinin epitope) in strains grown at
25uC and 37uC through Western blotting using anti-HA
antibodies (Figure 2). The CovRIFD strain produced the HasA
protein 18 times higher at 25uC than at 37uC (compared using
NIH ImageJ for densitometry), indicating that capsule thermo-
regulation occurs at a post-transcriptional level. As expected, the
HasA protein was not detected from the wild type HSC5 at either
temperature. The size of the HasA protein on the Western blot
was the same as that calculated from the gene size and was the
same between cells grown at 25uC and 37uC, revealing no obvious
post-translational modification of HasA.
Taken together, capsule thermoregulation is governed at a post-
transcriptional level, possibly at the translational level. Once the
transcriptional repression by CovR is derepressed, capsule genes
are transcribed at the same rate regardless of temperature but the
production of HasA is apparently derepressed at 25uC relative to
37uC.
HSC5 and MGAS315 do not exhibit extracellular
hyaluronidase activity
Another factor that can influence the capsule production other
than capsule synthesis rate is the degradation rate of hyaluronic
acid capsule. Since some GAS strains (,9% [39] or ,23% [40])
produce an extracellular hyaluronidase that can degrade the
hyaluronic acid capsule [40,41], we examined if the strains HSC5
and MGAS315 produce the functional extracellular hyaluronidase
HylA. All the GAS strains sequenced so far contain the sequence
of hylA. However, the majority of GAS strains, which do not
exhibit extracellular HylA activity, have mutations in hylA [39].
The strains we used also have mutations in hylA, compared to the
full-length hylA gene of MGAS10750 (serotype M4), indicating
that our strains do not produce functional HylA. The hylA gene of
HSC5 (serotype M14) is terminated early by a nonsense mutation
(Q806 to Ochre stop codon) resulting in a 63-amino acid
truncation. The hylA gene of MGAS315 (serotype M3) has an
inframe deletion resulting in a 61 amino acid deletion near the N-
terminus of HylA. These mutations have been reported previously
to produce non-functional HylA [39]. Consistent with this
sequencing analysis, both our wild type strains and their CovR2
strains did not exhibit extracellular hyaluronidase activity either at
25uC or 37uC in a plate diffusion assay described elsewhere [34]
(unpublished data).
Table 2. The amount of capsule produced by S. pyogenes strains at different temperatures.
Strain name Description Capsule produced (fg/cfu)
%
at 376C at 306C at 256C
HSC5 Wild type, M14 serotype 40.760.4 46.161.3 41.164.7
VCovR HSC5 CovRS2 strain created by insertional disruption 37.060.3 276.1610.9 755.7673.7
CovRIFD HSC5 CovR2 strain created by in-frame deletion 39.965.8 353.6645.7 672.3610.1
VCovR (pCovRS) VCovR complemented with covRS in trans 42.364.0 49.860.3 42.065.9
CovRIFD:VSPy_2199 CovRIFD with disrupted SPy_2199, the immediate upstream gene of the capsule
operon
29.9612.0 ND* 656.1639.6
MGAS315 Wild type, M3 serotype 85.560.7 ND* 84.262.5
MGAS31:VCovR MGAS315 CovR2 strain created by insertional disruption 95.464.5 ND* 803.865.2
*ND: Not Determined.
%fg/cfu, femtogram per colony forming unit. Capsule quantitation was performed in triplicate for each sample and at least twice per each strain. The values shown here
are average 6 standard error.
doi:10.1371/journal.pone.0037367.t002
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Occurrence of the mucoid phenotype among invasive
GAS
The CDC Streptococcus Laboratory routinely notes the presence
or absence of the highly mucoid phenotype among the invasive
GAS received for characterization from Active Bacterial Core
surveillance (ABCs). Among 2850 invasive isolates collected during
2007–2010 surveillance in 10 states, 59 isolates (2.1%, from 7
different states) displayed obvious excess production of capsule on
sheep blood agar (SBA) plates. Type emm1 (subtype emm1.0)
represented 29 (49.2%) of these isolates, with types emm6, emm11,
and emm118 accounting for 5 isolates each. Types emm3 and emm89
each accounted for 4 isolates. Type emm1 was the most common
invasive type overall during 2007–2010, accounting for .23% of
the total isolates, while the other 5 emm types accounting for 4–5
mucoid isolates occurred within 2.1%–7% of total invasive
isolates.
Capsule thermoregulation occurs among invasive clinical
isolates of S. pyogenes
To examine the presence of capsule thermoregulation in clinical
isolates, we tested 115 invasive isolates that were obtained through
the CDC’s Emerging Infections Program/Active Bacterial Core
surveillance (ABCs) during 2007–2010. Among these 115 isolates,
53 isolates were mucoid on THY agar plates at 25uC and/or
37uC. Most of these mucoid strains had already exhibited mucoid
phenotype in the CDC’s screening using sheep blood agar plates.
Among the 53 mucoid isolates, 11 (21%), representing 5 different
emm types, demonstrated capsule thermoregulation in that they
were observed to produce more capsule at the lower temperature
(Table 3). The lab strains, HSC5 and MGAS315, exhibited
capsule thermoregulation only when CovR-mediated transcrip-
tional repression was released by mutations of the covRS genes.
Since mutations in covRS have been reported to be frequently
observed in invasive clinical isolates [42,43], we tested if the eleven
CDC strains that exhibited capsule thermoregulation contained
mutations in the covRS genes. First, we introduced the pCovRS
plasmid to the eleven CDC strains and examined the phenotype
for capsule thermoregulation. The introduction of pCovRS
abolished capsule production of all the capsule-thermoregulated
invasive isolates at either temperature (Table 3). This result
indicates that the introduction of pCovRS complemented defec-
tive CovRS-mediated repression of the hasABC operon, so both or
either CovR or CovS would be nonfunctional in those clinical
isolates. For further confirmation of the complementation analysis,
we sequenced the covRS region of the 11 isolates. As expected, all
11 isolates contained mutation within covR or covS (Table 4).
Interestingly, mutation in covS was dominant in these isolates; eight
isolates have mutations in covS and only three isolates have
mutations in covR. Most mutations (7 out of 8) in covS were frame
shift mutations causing early termination of translation, and these
frame shift mutations were caused by deletion of redundant
sequences (isolates 2, 17, 36, 37, 53) or duplication of a sequence
(isolates 9 and 47). The most frequent deletion was deletion of a
thymine out of a 7 consecutive thymine sequence. On the other
hand, all of the three mutations in covR were missense mutations,
of which two were previously reported to confer the mucoid
phenotype [42,43].
Another eleven CDC lab isolates (isolate # 4, 7, 20, 30, 38, 39,
44, 48, 49, 51, 52) among the 53 mucoid invasive isolates were
highly mucoid regardless of incubation temperature, indicating
that both the transcriptional repression by the CovRS system and
capsule thermoregulation do not function in these strains. As
expected, complementation with pCovRS reduced the mucoidity
of these strains at the same degree at both incubation tempera-
tures. Several isolates (isolate # 4, 30, 38, 48) exhibited some
mucoidity after pCovRS complementation, even though the
degree of mucoidity decreased (Table 3). S. pyogenes mucoidity is
dependent on not only the functionality of the CovRS system but
also the sequence of the capsule promoter region where CovR
binds [44]. Thus, the CovR binding sites in the capsule promoter
region of the strains exhibiting some mucoidity after the
complementation with pCovRS might have less affinity for CovR.
CvfA, an endoribonuclease, is required for capsule
thermoregulation
In order to identify genes or chromosomal loci that influence
capsule thermoregulation, transposon mutagenesis was performed
using a Tn4001 derivative containing the kanamycin resistance
gene, aphA-3. The transposon has a strong Rho-independent
transcriptional terminator at both ends of aphA-3, so no leakage of
Figure 2. Capsule thermoregulation occurs at the production
level of the capsule synthesis proteins. The first-translated capsule
synthesis protein HasA was tagged with the HA (hemagglutinin)
epitope through homologous recombination. The strains with HA-
tagged HasA were grown on THY agar plates overnight. After being
incubated further for another six to eight hours at 25uC or 37uC
respectively, the colonies were collected and lysed with a bead beater.
10 mg of protein from each cell extract was loaded on 8% SDS-PAGE gel
and electrophoresed. Western blotting against HA-tag or Spy_2184
(internal control) was then performed to examine the expression level
of HasA according to temperature change. Figure A: The CovR2 strain
produced ,18 times more HasA at 25uC than 37uC. On the other hand,
the wild type did not produce a detectable amount of HasA, regardless
of the incubation temperatures. Figure B: The transposon-generated
CvfA2 capsule overproducer at any temperature also overproduced
HasA regardless of the incubation temperatures. Taken together with
the result from Figure 1B, the thermoregulation of capsule production
occurs at the production level of the capsule synthesis proteins. The
following strains were used. Figure A: wild type (WT), HasA-HA; CovR2
strain (CovR2), CovRIFD:HasA-HAkm. Figure B: CovR2 strain (CovR2),
CovRIFD:HasA-HAspc; CovR2 CvfA2 strain (CovR2 CvfA2); Cov-
RIFD:TnCvfA1:HasA-HA.
doi:10.1371/journal.pone.0037367.g002
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Table 3. Capsule production by mucoid invasive S. pyogenes strains at different temperatures.
CDC lab
isolate ID# Source emm subtype
Mucoid at
376C*
Mucoid at
256C*
Capsule thermo-
regulation pCovRS complementation@
Mucoidity at 376C*
Mucoidity at
256C*
1** Blood emm1.0 + + No
2 Blood emm3.1 2 +++ Yes 2 2
3** Blood emm11.0 2 +++ Yes 2 2
4 Blood emm18.0 +++ +++ No + +
5 Blood emm95.0 + + No
6** Blood emm118.0 ++ ++ No
7 Cerebral Spinal Fluid emm122.2 +++ +++ No 2 2
8 Blood stns554.0% ++ ++ No
9** Blood emm89.0 + ++ Yes 2 2
10** Fascia Tissue emm1.0 + + No
11** Blood emm11.0 + + No
12** Blood emm1.0 + ++ Yes 2 2
13** Blood emm1.0 + + No 2 2
14** Blood emm1.0 ++ ++ No
15** Blood emm1.0 + + No
16** Pleural Fluid emm6.0 ++ ++ No
17** Blood emm89.0 ++ +++ Yes 2 2
18** Blood emm1.0 + + No
19** Blood emm1.0 + + No
20** Blood emm118.0 +++ +++ No 2 2
21** Blood emm1.0 ++ ++ No
22** Blood emm1.0 + + No
23** Blood emm6.4 ++ ++ No
24** Blood emm6.74 ++ ++ No
25** Blood emm1.0 + + No
26** Blood emm11.0 ++ ++ No
27** Blood emm1.0 + + No
28** Blood emm1.0 + + No
29** Blood emm1.0 ++ ++ No
30** Blood emm83.1 +++ +++ No + +
31** Blood emm3.1 + + No
32** Blood emm11.0 + + No
33** Blood emm1.0 ++ ++ No
34** Blood emm1.0 + + No
35** Blood st4722.0% + + No
36** Blood emm1.0 + +++ Yes 2 2
37** Blood emm1.0 ++ +++ Yes 2 2
38** Blood stPA57.3% +++ +++ No ++ ++
39** Blood emm44.0 +++ +++ No 2 2
40** Blood emm89.0 ++ ++ No
41** Blood emm1.0 ++ ++ No
42** Blood emm3.1 ++ ++ No
43** Blood emm1.0 ++ ++ No
44** Blood emm1.0 +++ +++ No 2 2
45** Blood emm1.0 ++ ++ No
46** Blood emm1.0 ++ +++ Yes 2 2
47** Blood emm3.1 + +++ Yes 2 2
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transcription from the transposon occurs. The covR in-frame
deletion strain, CovRIFD, was used as the capsule-thermoregu-
lated background strain for the transposon mutagenesis. Among
transposon-generated mutants, eight strains produced no capsule
at either 25uC or 37uC. DNA sequencing to identify the
transposon insertion site revealed that each of these strains that
lacked capsule production at either temperature contained a
transposon insertion within the hasABC operon, confirming that
the over-produced capsular material from the CovR null strains at
25uC was hyaluronic acid. Among transposon-generated mutants,
two strains in which the transcription of the cvfA gene (Spy_1633)
was disrupted by an insertion of the transposon overproduced
capsule at both temperatures. In these strains, CovRIFD:TnCvfA1
and CovRIFD:TnCvfA2 (covR in-frame deletion strain with a
Table 3. Cont.
CDC lab
isolate ID# Source emm subtype
Mucoid at
376C*
Mucoid at
256C*
Capsule thermo-
regulation pCovRS complementation@
Mucoidity at 376C*
Mucoidity at
256C*
48** Blood emm18.0 +++ +++ No + +
49** Blood emm59.0 +++ +++ No 2 2
50** Pleural Fluid emm118.0 ++ +++ Yes 2 2
51** Blood emm118.0 +++ +++ No 2 2
52** Blood emm118.0 +++ +++ No 2 2
53** Blood emm11.0 + +++ Yes 2 2
#Isolates were recovered through Active Bacterial Core surveillance for S. pyogenes during 2007–2010 in the United States. Refer to surveillance reports at http://www.
cdc.gov/abcs/reports-findings/surv-reports.html.
%New emm subtypes that have not yet been provided emm designations. All emm designations are shown at the downloadable database ftp://ftp.cdc.gov/pub/
infectious_diseases/biotech/tsemm/.
*Mucoidity assay was performed with colonies grown on THY (Todd Hewitt Yeast) agar plates.
2 : Basal level capsule production (less than 100 fg/cfu), not observable with visual inspection such as HSC5 or MGAS315 wild type.
+ : Capsule production of 100–300 fg/cfu, barely detectable with visual inspection.
++ : Capsule production of 300–500 fg/cfu, clearly detectable with visual inspection but less amount of capsule production than HSC5 CovRS null mutants incubated at
25uC.
+++ : Capsule production of more than 500 fg/cfu, clearly detectable with visual observation, almost the same amount of capsule production as HSC5 CovRS null
mutants incubated at 25uC.
**These strains were preselected as being mucoid on blood agar plates by CDC.
@Blank cells: Values were not determined.
doi:10.1371/journal.pone.0037367.t003
Table 4. Alterations in the covRS sequence of strains exhibiting capsule thermoregulation.#
CDC lab isolate ID Mutated gene Type of mutation* Consequence of mutation% Reference
2 covS Frame shift (deletion of nt 77)a Early termination after aa residue 35 [42,43]
3 covR Missense mutation M86V [42]
9 covS Frame shift (insertion of 11 bps
between nt 82 and nt 83)b
Early termination after aa residue 39 [43]
12 covS Missense mutation T35I, V57G This study
17 covS Frame shift (deletion of nt 77)a Early termination after aa residue 35 [42,43]
36 covS Frame shift (deletion of nt 77)a Early termination after aa residue 35 [42,43]
37 covS Frame shift (deletion between
nt 1205 and nt 1211)c
Early termination after aa residue 407 [43]
46 covR Missense mutation A81T This study
47 covS Frame shift (insertion of 11 bps
between nt 88 and nt 89)d
Early termination after aa residue 39 [43]
50 covR Missense mutation R94C [42,43]
53 covS Frame shift (deletion of nt 77)a Early termination after aa residue 35 [42,43]
#The CovRS sequences of CDC lab isolates were compared to the CovRS sequences of 11 genome-sequenced strains publically available at the NCBI website, http://
www.ncbi.nlm.nih.gov/genomes/lproks.cgi.
*Nucleotide sequence level; nt, nucleotide.
%Protein sequence level; aa, amino acid.
aDeletion of a thymine out of 7 consecutive thymines.
bDuplication of 11 bps of TCTGCATTTTC.
cDeletion of 5 bps of AAAGA out of AAAGAAAAGA.
dDuplication of 11 bps of TTTTCTCTGCC.
doi:10.1371/journal.pone.0037367.t004
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transposon insertion preventing cvfA transcription), the transposon
was inserted in the location just upstream of the start codon of cvfA
(Figure 3 A). Capsule amount from these strains increased more
than 10-fold at 37uC, compared to that of CovRIFD (Figure 3 B),
while capsule gene transcription within these transposon-generat-
ed capsule overproducers changed very little. The capsule
transcript ratio of CovRIFD:TnCvfA1 to CovRIFD was
2.3760.41 (mean 6 standard deviation) at 25uC and 2.0160.55
at 37uC (Figure 3 C).
Previous Western blot analysis exhibited that the overproduced
capsule amount by CovRIFD at 25uC was directly correlated with
the amount of the capsule synthesis proteins. As expected, the
capsule amount produced by the transposon-generated capsule
overproducers also directly correlated with the amount of the
capsule synthesis proteins; the mutant strain CovRIFD:TnCvfA1
overproduced HasA regardless of the incubation temperature, so it
produced higher amounts of HasA than the background strain
CovRIFD at 37uC (Figure 2 B). These results are consistent with
capsule thermoregulation occurring at a post-transcriptional level.
Our previous work indicated that the cvfA gene is monocistronic
and its disruption does not affect the expression of downstream
genes [17]. To confirm that the lack of cvfA expression due to the
transposon insertion was solely responsible for the phenotype of
capsule overproduction, the cvfA gene and promoter region were
amplified, inserted into the suicide vector pSPC18 and transferred
into the transposon-generated capsule overproducer, Cov-
RIFD:TnCvfA1, as previously described [17]. This cis-comple-
mented strain, CovRIFD:TnCvfA1Comp, exhibited capsule
thermoregulation identical to the parental strain (Figure 3 B),
verifying that cvfA is required for thermoregulation of capsule
synthesis.
Complementation analysis with the capsule genes
expressed in trans under a heterologous promoter
confirms that thermoregulation occurs at the post-
transcriptional level where CvfA is required
S. pyogenes strains were transformed to express the capsule genes
in trans under the rofA promoter and the phenotype was examined
for capsule thermoregulation (Figure 4). Expression of the
chromosomal capsule genes was blocked by disrupting the first
gene of the capsule operon hasA in order to examine only the
influence of ectopically expressed hasABC. The capsule genes
under the rofA promoter were not expressed in the wild type strain
HSC5. One of the five CovR-binding sites in the capsule promoter
region resides at the end of the 59 side of hasA (refer to Figure 5),
and that CovR binding site has the strongest transcription
inhibitory activity [45]. As expected, when the covR gene was
deleted, the strain CovRIFD:VHasA(pHasABC), exhibited capsule
thermoregulation, indicating that the native capsule gene
promoter is not required for capsule thermoregulation. This result
also confirms that capsule thermoregulation occurs at a post-
transcriptional level. When the CvfA2 capsule overproducer was
transformed with pHasABC, the strain CovRIFD:TnCvfA1:VHa-
sA(pHasABC) overproduced capsule regardless of incubation
temperature. Thus, CvfA is required for capsule thermoregulation
even when the capsule genes are expressed under a heterologous
promoter in trans.
Discussion
S. pyogenes strains have been classified as non-mucoid or mucoid
depending upon capsule production under laboratory growth
conditions (mostly grown on rich media at 37uC anaerobically).
While some strains do not produce capsule under laboratory
growth conditions, genomes of all S. pyogenes strains contain the
intact hasABC capsular biosynthetic operon, suggesting that certain
factors or conditions for capsule production by non-mucoid strains
might be missing. It is known that CovR, the response regulator of
the CovRS two-component system, binds to the promoter region
of the capsule operon and represses the transcription of capsule
genes, consistent with the observation that spontaneous mutations
Figure 3. CvfA is required for the thermoregulation of capsule
production. A) Transposon insertion sites in the transposon-generated
CvfA2 mutants. The nucleotide sequence in front of the start codon of
cvfA is shown. The horizontal arrow represents 59- side of the cvfA gene.
The putative 210 promoter element and transcription start site (+1) are
indicated in bold. Each transposon insertion site in the transposon-
generated CvfA2 strains was shown with a vertical arrowhead:
transposon insertion between G and T in the CovRIFD:TnCvfA1 strain
and between A and C in the CovRIFD:TnCvfA2 strain. These transposon
insertions eliminated thermoregulation of capsule production. B) The
transposon-generated CvfA2 mutant regained the phenotype of
capsule thermoregulation upon cis-complementation. The transposon
insertions that prevent the expression of cvfA abolished the capsule
thermoregulation of the CovR2 background strain; the transposon-
generated CvfA2 strain overproduced capsule regardless of the
incubation temperatures. The introduction of an intact copy of cvfA
into the chromosome of the transposon-generated CvfA2 strain (cis-
complementation) restored capsule thermoregulation. C) The transpo-
son-generated CvfA2 mutation did not influence the capsule gene
transcription even at 25uC. The transposon-generated CvfA mutant was
grown on THY agar plates at 37uC overnight (,18 hrs) and the fully-
grown colonies were incubated for another six to eight hrs at each
temperature (25uC or 37uC). The quantity of the capsule transcript in the
strain was then measured with real time-RT (reverse transcriptase) PCR
and compared to that in the CovR2 background strain. The following
strains were used: CovR2 strain (CovR2), CovRIFD; CvfA2 CovR2 strain
(CovR2CvfA2), CovRIFD:TnCvfA1; CvfA complemented strain of Cov-
RIFD:TnCvfA1 (CovR2CvfA2pCvfA), CovRIFD:TnCvfA1Comp.
doi:10.1371/journal.pone.0037367.g003
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Figure 4. Expression of the capsule genes in trans under a heterologous promoter also exhibits capsule thermoregulation. The
hasABC genes were expressed in trans under the rofA promoter on pHasABC and transferred to S. pyogenes HSC5 strains whose expression of
chromosomal capsule genes was blocked by disrupting the first transcribed capsule gene, hasA. Those complemented strains with pHasABC
exhibited the same phenotype of capsule thermoregulation as the strains whose capsule genes were expressed under the native promoter on the
chromosome. The following strains were used: CovR2 strain (CovR2), CovRIFD; chromosomal capsule gene knock-out strain (HasABC2), VHasA; in
trans capsule gene complemented strain (HasABC2(pHasABC)), VHasA(pHasABC); CovR2 HasABC2 strain (CovR2 HasABC2); CovRIFD:VHasA; CovR2
HasABC2 strain complemented with pHasABC (CovR2 HasABC2 (pHasABC)), CovRIFD:VHasA(pHasABC); CovR2 CvfA2 HasABC2 strain (CvfA2 CovR2
HasABC2), CovRIFD:TnCvfA1:VHasA; CovR2 CvfA2 HasABC2 strain complemented with pHasABC (CvfA2 CovR2 HasABC2 (pHasABC)),
CovRIFD:TnCvfA1:VHasA(pHasABC).
doi:10.1371/journal.pone.0037367.g004
Figure 5. Regulation of capsule production by S. pyogenes strains, HSC5 and MGAS315. Capsule production by the non-mucoid S.
pyogenes strains, HSC5 and MGAS315, is regulated both at the transcriptional and post-transcriptional level. Phosphorylated CovR binds to its binding
sites in the capsule promoter region, and represses hasABC transcription [45]. A thermoregulatory system regulates the production of capsule
synthesis proteins at a post-transcriptional level. Capsule production occurs only when CovR is not bound to the hasABC promoter region and
environmental temperature is lower than 37uC.
doi:10.1371/journal.pone.0037367.g005
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within the two-component system covRS genes confer the mucoid
phenotype [42]. The influence of environmental temperature
upon capsule production by CovRS defective strains has not been
previously described.
As expected, we found in our lab strains that when covR was
inactivated, the amount of capsule gene transcript dramatically
increased (Figure 1). Still, only when these CovR null strains were
grown at sub-body temperature was a very large increase in
capsule production observed (Table 2). Our study indicates that
while the transcription of capsule genes is controlled in a
temperature-independent manner by the CovRS two-component
system, a post-transcriptional regulation of capsule production
occurs in a temperature-dependent manner (Figure 5).
Why does S. pyogenes overproduce capsule at sub-body temper-
ature? The capsule is composed of hyaluronic acid polymer
identical to that found in human connective tissue, and binds to
CD44 on keratinocytes in the pharyngeal mucosa and the skin [5].
Major functions of increased capsule production may be to protect
from desiccation and to increase the efficiency of initial attachment
to new host epithelial cells, thus promoting the spread of the
organism amongst the human population. Such roles are
consistent with S. pyogenes optimally producing the capsule outside
or on the surface of the host epithelial layers, where the
temperature is usually lower than the body temperature.
Consistent with this notion, our results show that in strains
thermoregulated for capsule synthesis, capsule production de-
creases when temperature increases (Table 2). Nonetheless, it is
likely that the enhanced capsular layer serves to protect strains
upon initiation of systemic infection [46,47,48]. Possibly, soon
after invasion through the epithelial layer, enhanced capsular
expression may not be required to evade phagocytosis due to
expression of M protein and/or other antiphagocytic factors
including streptococcal C5a peptidase. Husmann et al. showed
that capsule is required for pharyngeal colonization and increased
survival in the lower respiratory tract resulting in pneumonia in
respiratory infection mouse models [4]. However, capsule plays a
much smaller role in resistance to phagocytosis than M protein in
human blood [4]. These results agree with our hypothesis that
capsule increases invasion (penetration) by enhancing adherence
to keratinocytes at lower temperature and capsule might not be
required for evading phagocytosis due to the presence of other
antiphagocytic factors.
Paradoxically, S. pyogenes has been known to exhibit an
extracellular hyaluronidase activity that cleaves the 1.4 ß-linkage
between N-acetylglucosamine and D-glucuronic acid, the repeat-
ing subunit of hyaluronic acid capsule. However, contrary to
popular belief, only a small fraction (,9% [39] and,23% [40]) of
clinical strains exhibit the extracellular hyaluronidase activity.
Most invasive strains including M1 and M3 serotypes do not
exhibit the extracellular hyaluronidase activity, stressing the
importance of capsule in invasive S. pyogenes strains [39]. The
genome of S. pyogenes contains several hyaluronidase genes, one in
the GAS chromosome and the others in prophage genes. Among
these hyaluronidases, only the product of hylA, the hyaluronidase
gene encoded in the GAS chromosome, is attributable to the
extracellular hyaluronidase activity [40,41]. Other hyaluronidases
encoded in phage genes appeared not to be exported into the
extracellular milieu [40], suggesting that the role of these
prophages’ hyaluronidases is to help the prophages escape from
their encapsulated host. The majority S. pyogenes strains, which do
not exhibit the extracellular hyaluronidase activity, possess
mutations in hylA. Our lab strains, HSC5 and MGAS315, do
not produce the functional extracellular hyaluronidase since hylA
in both strains have mutations that have been reported previously
to produce non-functional HylA [39]. Thus, the extracellular
hyaluronidase HylA, which can degrade the hyaluronic acid
capsule, does not affect our interpretation of the post-transcrip-
tional capsule thermoregulation. Another line of evidence that
HylA does not play a major role in capsule thermoregulation is the
Western blot analysis (Figure 2), which exhibits a direct correlation
between the amount of the capsule synthesis proteins and the
amount of capsule produced. Taken together, these results indicate
that capsule thermoregulation occurs directly by the regulation of
the production of the capsule gene products, not by indirect
mechanism such as the regulation of the extracellular hyaluron-
idase, HylA.
We tested invasive S. pyogenes isolates provided by the CDC for
capsule thermoregulation and found that capsule thermoregula-
tion is a common feature, with 21% of the mucoid isolates
displaying the capsule thermoregulation phenotype. As expected,
those isolates displaying capsule thermoregulation contained
mutations within the covRS genes. This result confirms previous
reports that CovRS mutation is frequent among clinical invasive
strains [42,43]. When Ikebe et al. examined a panel of clinical
isolates from cases of invasive human infections, nearly half of
them (76 out of 164 isolates) contained mutations in CovR or
CovS [43]. Also, spontaneous emergence of CovRS2 mutants was
observed from a murine skin infection model, where it was
demonstrated that these mutations enhanced strain virulence and
increased severity of infection [42]. These findings indicate that
mutations within covRS are selected in vivo due to the better survival
through increased virulence factor expression. Unlike activators
for virulence gene expression, mutations in the CovRS two-
component system, a repressor system, increases the expression of
many virulence factors. Our discovery of capsule thermoregulation
among naturally occurring virulent covRS mutation strains is
another potentially important aspect of the virulence triggering
mechanism in this organism [49], especially by the emm1 strains
that we found to over-represent mucoid invasive isolates.
Even though only covRS mutation strains display capsule
thermoregulation under the assay condition we applied, wild type
strains with functional CovRS such as HSC5 and MGAS315 may
be capable of exerting capsule thermoregulation in natural
infection locations such as on the skin or the mucosal surface. In
many bacterial species, response to environmental stress is
mediated by secondary sigma factors. S. pyogenes, however, does
not contain stress-responsive sigma factors, and the role of stress-
response in GAS appears to be largely mediated by the CovRS
two-component system which is required for growth under adverse
conditions such as elevated temperature [36], low pH [36], high
salt concentration [36], low magnesium [50], iron starvation [51],
and the presence of the cationic human antimicrobial peptide LL-
37 [51,52]. In these conditions, CovR is dephosphorylated and the
transcriptional repression by CovR is released. The epithelial
surface of infection sites could provide the stress conditions that
result in CovR dephosphorylation, including the lack of certain
nutrients (magnesium and iron for example), acidic pH [53], and
the presence of antimicrobial peptides.
Several mechanisms of thermoregulation have been discovered
in bacterial pathogens, involving DNA supercoiling, mRNA
secondary structure, and regulatory proteins. The degree of
DNA supercoiling, which modulates the binding of regulatory
proteins, is associated with thermoregulation [54,55,56,57,58,59].
Previous studies suggest that histone-like proteins such as H-NS
modulate gene expression based upon the degree of DNA
supercoiling [56,60,61,62,63]. Changes in mRNA secondary
structure, ‘‘riboswitches’’, can confer thermoregulation. For
example, the secondary structures of the Shine-Dalgarno region
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of lcrF mRNA in Yersinia pestis [64] and prfA in Listeria monocytogenes
[65] change in response to temperature shift. At body temperature
(37uC), a loop structure of the mRNAs of lcrF and prfA melts,
which frees the Shine-Dalgarno region from their secondary
structures and allows translation to proceed. Some DNA-binding
regulators exhibit differential affinity to their DNA binding sites at
different temperatures. This type of thermoregulation requires
DNA-binding regulators to be post-translationally modified [2,66],
to interact with other factors [67,68,69], or to undergo confor-
mational changes [70] upon temperature shift. Thermoregulation
mechanisms controlled by DNA-binding proteins or by DNA-
supercoiling status are unlikely to be involved in capsule
thermoregulation in S. pyogenes since capsule thermoregulation
occurs at a post-transcriptional level. Also, a typical riboswitch
does not appear to govern capsule thermoregulation in S. pyogenes
since capsule thermoregulation exhibits higher quantities of
capsule at lower temperature. It appears likely that capsule
thermoregulation in S. pyogenes involves a novel mechanism that
has not yet been explored.
The expression of S. pyogenes pili is also thermoregulated; they
are expressed more at sub-body temperature (30uC) than body
temperature (37uC) [71]. The pili are also adhesin molecules
binding both human tonsil epithelium and primary human
keratinocytes [72]. Since both capsule and pili are adhesins and
expressed more at sub-body temperature, these certainly indicate
the benefit of thermoregulation of these adhesins for binding and
subsequent penetration. The underlying mechanism of pili
thermoregulation has not yet been studied but seems to be
different from that of capsule thermoregulation. Unlike capsule
thermoregulation, pili thermoregulation occurs at the transcrip-
tional level [71]. This pili thermoregulation appears to not be
mediated by the CovRS two-component system because the
expression level of the pili biogenesis genes in the cpa operon is the
same between the wild type and a CovR mutant [30].
CvfA was discovered during transposon mutagenesis experi-
ments screening for changes in capsule thermoregulation. Our
previous study showed that CvfA, a putative endoribonuclease,
also influences the expression of metabolic and virulence genes
depending on growth phase and nutritional stress, and that
influence is independent of the ppGpp-associated stringent
response [17]. In chemically defined media, CvfA represses the
expression of the genes of M protein (emm), streptokinase (ska), and
the CAMP factor (cfa) in carbohydrate deficient conditions, and
activates the expression of the gene of SpeB (speB) in peptide
deficient conditions. Recent studies of the CvfA ortholog in Bacillus
subtilis, RNaseY, indicate that the protein is an endoribonuclease
that interacts with glycolytic enzymes (enolase and phosphofruc-
tokinase), ribonucleases (PNPase and RNase J1), and an RNA
helicase (CshA) [73,74,75]. We also demonstrated that CvfA
interacts with the glycolytic enzyme enolase in S. pyogenes [17].
Since the RNA degradosome in E. coli is composed of components
(enolase, RNase E, PNPase, and an RNA helicase, RhlB) similar to
the proteins CvfA interacts with [73], CvfA appears to be a
component of the RNA degradosome of bacteria in the phylum of
firmicutes including S. pyogenes, S. aureus, and B. subtilis [73,74,75].
It appears that CvfA is not involved in the degradation of the
capsule mRNA since the CovR2CvfA2 strain produced almost
the same amount of capsule transcript as the CovR2 strain at both
25uC and 37uC. Thus, CvfA might affect the expression of a
regulator controlling capsule thermoregulation. In some cases, the
influence of CvfA on virulence gene expression is mediated by
regulators. For example, the production of the major secreted
protease SpeB is greatly reduced in the CvfA null strain, and this
reduction is restored to the wild type level when the major
transcriptional activator gene for speB expression, ropB, is
additionally expressed in trans in the CvfA null strain [17]. This
result indicates that CvfA influences the production of SpeB
through the transcriptional regulator RopB. Similarly, CvfA of
Staphylococcus aureus influences the expression of alpha-hemolysin
through SarZ, a positive transcriptional regulator [76]. Once the
transcriptional repression by CovR is derepressed, capsule genes
are transcribed at the same rate regardless of temperature, while
production of HasA is apparently de-repressed below 37uC. This
suggests that a repressor system for the translation of the capsule
gene transcript controls capsule thermoregulation and that CvfA
might influence the degradation of the repressor transcript
depending on environmental temperature. Our recent transposon
mutagenesis discovered two new chromosomal loci that influence
capsule thermoregulation. These transposon-generated mutants
showed the same phenotype as the transposon-generated CvfA2
mutant; they overproduced capsule regardless of incubation
temperature. One capsule overproducer has a transposon insertion
at 187 nucleotides upstream of the hasA start codon (110
nucleotides upstream of the 235 promoter element). It appears
that the region around the insertion site is not involved in
transcriptional regulation of capsule gene expression because the
transposon insertion site is far upstream of the capsule promoter
and capsule thermoregulation is controlled at the translational
level. Also, the region is not part of either the transcript of or
transcriptional regulation site for SPy_2199, the divergently
transcribed immediate upstream gene of capsule genes, because
the disruption of SPy_2199 does not influence capsule thermoreg-
ulation (Table 1). Thus, even though the transposon-inserted
region is not a part of the capsule gene transcript or a
transcriptional regulation site, the region is necessary for capsule
thermoregulation. This region does not encode an open reading
frame even for a small peptide, so it might encode a small non-
coding RNA. One possibility of CvfA’s role in capsule thermo-
regulation is through the regulation of this putative small non-
coding RNA expression. The other capsule overproducer had a
transposon insertion in a prophage gene. HSC5 has three
prophages on its chromosome. The prophage in which the
transposon inserted resides between the genes of excinuclease ABC
subunit A (the ortholog of Spy_1825) and putative divalent cation
transport protein (the ortholog of Spy_1827). The prophage gene
in which the transposon inserted is the ortholog of SpyM3_1254.
Thirty nine open reading frames exist downstream of SpyM3_1254
in the same direction, so SPyM3_1254 or a downstream gene or
genes could be responsible for the phenotype caused by the
transposon insertion (polar effect). Hence, one of those genes may
produce a regulator required for capsule thermoregulation, and
CvfA may influence the expression of the regulator.
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